Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. reports developments in precision medicine for transplant patients and caregivers. The company’s updates center on non-invasive molecular testing for heart, kidney, and lung transplantation, including AlloSure, AlloMap, HeartCare, and related evidence generation for post-transplant surveillance, risk assessment, and longitudinal patient management.
CareDx news also covers operating and financial results for testing services and patient and digital solutions, product and platform launches such as VANTx clinical data analytics, clinical conference presentations, material agreements, and Nasdaq-related governance matters including inducement equity awards.
CareDx, Inc. (NASDAQ: CDNA) announced a new study confirming that AlloMap, the only gene-expression profiling blood test for heart transplant rejection, significantly reduces pain and adverse events compared to heart biopsy. Conducted at Baylor University Medical Center, the study involved 43 patients and demonstrated that AlloMap's home testing option minimizes infection risk. The test has been FDA cleared since 2005 and is used in over 90% of U.S. heart transplant centers. The results support CareDx's commitment to enhancing patient experiences in transplant care.
Summary not available.
CareDx, Inc. (Nasdaq: CDNA) is set to host its annual digital health user conference, MEET, from September 18-20 in Las Vegas, Nevada. The event will gather professionals from transplant administration and healthcare to discuss innovations and best practices in transplant operations, patient management, and health equity. CEO Reg Seeto emphasized CareDx's commitment to patient-centered digital health solutions. Innovations such as the AlloCare mobile health app will be showcased, integrating various tools to streamline patient care processes.
Summary not available.
CareDx, Inc. (CDNA) announced its participation in the 29th International Congress of The Transplantation Society (TTS 2022) from September 10-14 in Buenos Aires, Argentina. Over 25 abstracts will be presented, showcasing the clinical applications of AlloSure® donor-derived cell-free DNA and AlloSeq cfDNA, including innovations in transplantation and artificial intelligence. CEO Reg Seeto emphasized the importance of this global presence, while Dr. Alexandre Loupy discussed AI's role in enhancing patient care. The announcement includes forward-looking statements regarding the potential benefits and risks associated with the event.
CareDx, Inc. announced its partnership with MOTTEP for a panel discussion aimed at tackling health disparities in organ transplantation, scheduled for August 18, 2022. The event will highlight the urgent need for improved health equity within organ donation, especially in minority communities, coinciding with National Minority Donor Awareness Month. Panelists include leading experts in the field, including Reg Seeto and Dr. Clive Callender. The discussion aims to raise awareness of the over 100,000 individuals awaiting organ transplants in the U.S., with a focus on high-risk, underserved populations.
CareDx, Inc. (Nasdaq: CDNA) reported its Q2 2022 financial results, achieving revenues of $80.6 million, up 9% year-over-year. The company delivered 45,000 patient test results, reflecting a 21% growth compared to Q2 2021. Despite a net loss of $21.7 million, the company boasts a strong capital position with $306 million in cash and no debt. CareDx revised its 2022 revenue guidance to $325 million to $335 million, attributing growth to an increased mix of commercial patients.
CareDx, Inc. (Nasdaq: CDNA) announces the integration of MedActionPlan PRO into its AlloCare® mobile health app, enhancing patient-clinician interaction. The platform simplifies post-transplant medication adherence, utilized by over 140 transplant centers. The AlloCare app, downloaded over 50,000 times, now offers personalized education and reminder alerts, empowering patients in their health management. Medication non-adherence poses risks for transplant success, with studies indicating up to 60% of non-adherence is unintentional. CareDx aims to improve transplant outcomes through this innovative integration.
CareDx, Inc. (Nasdaq: CDNA) has launched AlloHome™, a comprehensive patient monitoring solution aimed at enhancing care for transplant patients. This innovative technology allows patients to track vital health data at home, enabling healthcare providers to identify potential adverse events early. Studies indicate significant hospital readmission rates post-transplant, highlighting the need for continuous monitoring. CEO Reg Seeto emphasizes the importance of this tool, especially for patients in underserved communities, as it improves patient engagement and reduces complications.
CareDx, Inc. (NASDAQ: CDNA) will release its second quarter 2022 financial results after market close on August 4, 2022. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, with participation options available via phone or webcast. CareDx specializes in diagnostic solutions for transplant patients, emphasizing high-value healthcare services. The company's focus on precision medicine underscores its role as a leader in providing genomics-based information for transplant care.